Comparative Pharmacology
Head-to-head clinical analysis: PRONESTYL versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRONESTYL versus SOTYLIZE.
PRONESTYL vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic